Approval

China Approves Eravacycline 100 mg

China's National Medical Products Administration approved a new 100 mg strength of Everest Medicines' eravacycline product, 依嘉. The product's 50 mg strength was approved in China in 2023 for adults with complicated intra-abdominal infection. The company says the new strength may reduce preparation steps and drug waste for some patients and improve supply flexibility.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call